EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models

Haiting Liu, Hui Zhu, Lei Fu, Weiyan Zhang, Xi Chen, Bin Wang, Shaochen Guo, Yangming Ding, Ning Wang, Dongshuo Li, Yu Lu iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01399-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Haiting Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beij…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Oxazolidinones, Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Hospitals Authority Clinical Medicine Development of Special Founding Support, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Linezolid (LZD) was the first oxazolidinone approved for treating drug-resistant tuberculosis. A newly approved regimen combining LZD with bedaquiline (BDQ) and pretomanid (PMD) (BPaL regimen) is the first 6-month oral regimen that is effective against multidrug- and extensively drug-resistant tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisOxazolidinonesTuberculosis, Multidrug-ResistantExtensively Drug-Resistant TuberculosisAnimalsMiceLinezolidAntitubercular AgentsDisease Models, AnimalDiarylquinolinesNitroimidazoles

Stichwörter der Autor:innen

OTB-658linezolidmurine modelregimentuberculosis

Substanzen

LinezolidAntitubercular AgentsDiarylquinolinesOxazolidinonespretomanidNitroimidazoles

Autor:innen und Institutionen

  • Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, Peopl…

ORCID-Profile: Yu Lu

Förderung

  • Beijing Hospitals Authority Clinical Medicine Development of Special Founding Support
  • National Natural Science Foundation of China

Zitieren

APA

Liu, H., Zhu, H., Fu, L., Zhang, W., Chen, X., Wang, B., Guo, S., Ding, Y., Wang, N., Li, D., & Lu, Y. (2023). Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01399-22

Vancouver

Liu H, Zhu H, Fu L, Zhang W, Chen X, Wang B, et al. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01399-22

BibTeX
@article{Liu2023,
  author = {Liu, Haiting and Zhu, Hui and Fu, Lei and Zhang, Weiyan and Chen, Xi and Wang, Bin and Guo, Shaochen and Ding, Yangming and Wang, Ning and Li, Dongshuo and Lu, Yu},
  title = {Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01399-22}
}
Kostenlos starten →